Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 17/20 | 0.47 |
| ▸ | ATXN2 | Q99700 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099694 | 0.90 | ENPP2 (0.42) | ENPP2ATXN2KCNH2 | |
| SCHEMBL17509111 | 0.84 | ENPP2 (0.45) | ENPP2ATXN2KCNH2HTR2AABAT | |
| SCHEMBL16103494 | 0.83 | ENPP2 (0.43) | ENPP2ATXN2TACR1PTGDR2 | |
| SCHEMBL16093608 | 0.83 | ENPP2 (0.44) | ENPP2ATXN2KCNH2TACR1PTGDR2 | |
| SCHEMBL16099824 | 0.83 | ENPP2 (0.44) | ENPP2ATXN2KCNH2 | |
| SCHEMBL16099784 | 0.82 | ENPP2 (0.44) | ENPP2ATXN2KCNH2HTR2AABAT | |
| SCHEMBL16099748 | 0.81 | ENPP2 (0.43) | ENPP2ATXN2KCNH2TACR1 | |
| SCHEMBL16099845 | 0.81 | ENPP2 (0.43) | ENPP2ATXN2KCNH2HTR2AABAT | |
| SCHEMBL16099805 | 0.81 | ENPP2 (0.43) | ENPP2ATXN2KCNH2TACR1 | |
| SCHEMBL16102646 | 0.80 | ENPP2 (0.42) | ENPP2ATXN2KCNH2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | ENPP2 1/4885ATXN2 110/4885KCNH2 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.